Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
4th China CrossChina's fiscal budget well implemented in 2023China's automobile manufacturing sector logs steady expansion in 2023China trade fair Indonesia kicks off in JakartaBotswana prepares for citrus entry into int'l marketsXizang reports robust foreign trade growth in JanIntelligent seedling breeding base enhances spring farming efficiency in ChongqingLok Sabha elections 2024: BJP vows to turn India into manufacturing hubChina's central bank to further optimize financial servicesInfographic: China
2.3908s , 6497.34375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Illustrations news portal